Author

Catherine Gratas

Centre National de la Recherche ScientifiqueORCID 0000-0002-9155-6906Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:proteomics· 1

Frequent Co-Authors

A. PerriniD· 1 shared Anne ClavreuliD· 1 shared Audrey RousseauiD· 1 shared Aurélien A. SérandouriD· 1 shared Béatrice ClemenceauiD· 1 shared Céline SalaudiD· 1 shared Claire PecqueuriD· 1 shared Clément Philippe DelannoyiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. PerrinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Functional diversity of Vγ9Vδ2 T cells overcomes glioblastoma state plasticity and antigen heterogeneity

Pierre Paris, Marine Devinat, Julianne Ceroni, Elodie Guiet, Jocelyn Ollier, Mélanie Laurent—Blond, Pauline Thomas, M. Gaudin, Noémie Joalland, A. Perrin, Clément Philippe Delannoy, Audrey Rousseau, Philippe Meneï, Emmanuel Scotet, François Paris, , Claire Pecqueur

This study shows that combining GD2/OAcGD2-specific CAR and unmodified Vγ9Vδ2 T cells can overcome glioblastoma heterogeneity by targeting both PN and MES tumor states.

bioRxiv · May 21, 2026 · PreprintCancer Biology

PARP inhibitor counteracts Temozolomide Resistance in Glioblastoma Multiforme

Édouard Samarut, Gaston Tabourel, Joséphine Briand, Yuna Landais, Catherine Gratas, Delphine Loussouarn, Gwenola Bougras-Cartron, Pierre‐François Cartron, François M. Vallette, Céline Salaud, Lisa Oliver, Aurélien A. Sérandour

This paper shows that combining temozolomide with the PARP inhibitor olaparib overcomes TMZ resistance in glioblastoma by restoring sensitivity in MMR-deficient and MGMT-expressing cells.

bioRxiv · Dec 13, 2024 · PreprintCancer Biology